Research Analysts Set Expectations for CRBU Q1 Earnings

Caribou Biosciences, Inc. (NASDAQ:CRBU) – Equities research analysts at Brookline Capital Management issued their Q1 2025 earnings estimates for shares of Caribou Biosciences in a research report issued on Tuesday, March 11th. Brookline Capital Management analyst L. Cann anticipates that the company will post earnings of ($0.40) per share for the quarter. The consensus estimate for Caribou Biosciences’ current full-year earnings is ($1.64) per share. Brookline Capital Management also issued estimates for Caribou Biosciences’ Q2 2025 earnings at ($0.48) EPS, Q3 2025 earnings at ($0.52) EPS, Q4 2025 earnings at ($0.66) EPS, FY2025 earnings at ($2.15) EPS, FY2026 earnings at ($2.24) EPS, FY2027 earnings at ($3.86) EPS and FY2028 earnings at ($1.74) EPS.

Caribou Biosciences (NASDAQ:CRBU) last released its earnings results on Monday, March 10th. The company reported ($0.39) earnings per share for the quarter, beating the consensus estimate of ($0.40) by $0.01. Caribou Biosciences had a negative net margin of 1,290.81% and a negative return on equity of 45.46%. The business had revenue of $2.08 million during the quarter, compared to analysts’ expectations of $2.11 million.

CRBU has been the subject of a number of other research reports. Citigroup cut their price target on shares of Caribou Biosciences from $30.00 to $6.00 and set a “buy” rating for the company in a research note on Tuesday, November 26th. Bank of America dropped their price objective on shares of Caribou Biosciences from $13.00 to $11.00 and set a “buy” rating for the company in a report on Tuesday, January 7th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $9.00 price objective on shares of Caribou Biosciences in a report on Friday, November 15th. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Caribou Biosciences has an average rating of “Buy” and a consensus price target of $10.33.

Caribou Biosciences Stock Down 0.9 %

Shares of CRBU opened at $1.06 on Thursday. The stock has a market cap of $95.99 million, a price-to-earnings ratio of -0.64 and a beta of 2.34. Caribou Biosciences has a 12 month low of $1.01 and a 12 month high of $5.94. The company has a 50-day moving average price of $1.40 and a two-hundred day moving average price of $1.79.

Institutional Trading of Caribou Biosciences

Hedge funds and other institutional investors have recently modified their holdings of the stock. Erste Asset Management GmbH acquired a new stake in shares of Caribou Biosciences in the third quarter valued at approximately $28,000. Centric Wealth Management acquired a new stake in shares of Caribou Biosciences in the fourth quarter valued at approximately $27,000. Intech Investment Management LLC acquired a new stake in Caribou Biosciences during the 3rd quarter worth $43,000. Russell Investments Group Ltd. grew its holdings in Caribou Biosciences by 859.0% during the 4th quarter. Russell Investments Group Ltd. now owns 23,909 shares of the company’s stock worth $38,000 after acquiring an additional 21,416 shares during the period. Finally, MetLife Investment Management LLC grew its holdings in Caribou Biosciences by 60.0% during the 4th quarter. MetLife Investment Management LLC now owns 24,404 shares of the company’s stock worth $39,000 after acquiring an additional 9,148 shares during the period. Institutional investors and hedge funds own 77.51% of the company’s stock.

About Caribou Biosciences

Caribou Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma.